Vol 17, No 2 (2012)
Published online: 2012-03-01

open access

Page views 138
Article views/downloads 155
Get Citation

Connect on Social Media

Connect on Social Media

Results of combined radiotherapy and hormonal treatment of prostate cancer patients with initial PSA value > 40ng/ml

Jiri Kubeš1, Cvek Jakub2, Vondráček Vladimir1, Dvořák Jan1, Argalacsová Sona1, Navrátil Matej1, Buřil Jan1
DOI: 10.1016/j.rpor.2012.01.006
Rep Pract Oncol Radiother 2012;17(2):79-84.

Abstract

Aim

To evaluate the outcome of prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Background

The outcome of prostate cancer patients with very high initial PSA value is not known and patients are frequently treated with palliative intent. We analyzed the outcome of radical combined hormonal treatment and radiotherapy in prostate cancer patients with initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml.

Methods

Between January 2003 and December 2007 we treated, with curative intent, 56 patients with non-metastatic prostate cancer and initial PSA value >40[[ce:hsp sp="0.25"/]]ng/ml. The treatment consisted of two months of neoadjuvant hormonal treatment (LHRH analog), radical radiotherapy (68–78[[ce:hsp sp="0.25"/]]Gy, conformal technique) and an optional two-year adjuvant hormonal treatment.

Results

The median time of follow up was 61 months. 5-Year overall survival was 90%. 5-Year biochemical disease free survival was 62%. T stage, Gleason score, PSA value, and radiotherapy dose did not significantly influence the outcome. Late genitourinal and gastrointestinal toxicity was acceptable.

Conclusion

Radical treatment in combination with hormonal treatment and radiotherapy can be recommended for this subgroup of prostate cancer patients with good performance status and life expectancy.

Article available in PDF format

View PDF Download PDF file



Reports of Practical Oncology and Radiotherapy